The Transthyretin Amyloidosis Outcomes Survey (THAOS), established in 2007, is a longitudinal, observational study open to all physicians treating, and all patients with, transthyretin (TTR) amyloidosis. The data collected by THAOS will be used to inform and educate clinicians about the disease and its management.
The THAOS.net website provides information for patients, their caregivers and physicians about TTR amyloidosis.
The first THAOS Investigator Meeting, held on 20–21 April 2013 in Prague was a huge success with over 130 attendees from across the world. Read more about the event
New data released by the THAOS registry show over 1800 patients are now enrolled. View the March data here